F-1/A: PomDoctor Limited Files Amended IPO Prospectus Amidst Going Concern Doubts, Highlighting Growth in Online Healthcare and Supply Chain

PomDoctor Limited, a Cayman Islands holding company operating a leading online medical services platform for chronic diseases in China, has filed an amended F-1 registration statement for its initial public offering, revealing continued net losses and a 'going concern' opinion from its auditor, despite revenue growth and increasing patient engagement.

Summary

• PomDoctor Limited is a Cayman Islands holding company primarily operating an online medical services platform for chronic diseases in China through its Variable Interest Entity (VIE) and its subsidiaries.
• The company is preparing for an Initial Public Offering (IPO) on the Nasdaq Global Market under the symbol POM, with an estimated initial public offering price per ADS between US$ and US$.
• The company reported net revenues of RMB304.9 million in 2023, increasing to RMB342.6 million (US$46.9 million) in 2024, representing a 12.4% growth.
• Despite revenue growth, PomDoctor incurred net losses of RMB36.9 million in 2023 and RMB37.4 million (US$5.1 million) in 2024.
• The company's auditor, Marcum Asia CPAs LLP, has expressed 'substantial doubt' about PomDoctor's ability to continue as a going concern due to recurring losses, negative operating cash flows, and a significant working capital deficit.
• As of December 31, 2024, the cumulative number of contracted doctors on the platform stabilized at over 212,800, and transacting patients increased from 654,817 in 2023 to 699,338 in 2024.
• The company's business model focuses on chronic disease management and pharmaceutical services, connecting patients to doctors and pharmaceutical products through an online platform.
• PomDoctor plans to use the net proceeds from the IPO for supply chain stocking (35%), expansion of departmental and geographic coverage (25%), working capital (20%), research and development (10%), and general corporate purposes.
• The company operates under a dual-class share structure, with Mr. Zhenyang Shi and Ms. Li Xu beneficially owning all Class B ordinary shares, granting them considerable influence over corporate matters.
• PomDoctor has completed the required filings with the CSRC for this offering, and the CSRC published the filing results on January 17, 2025.

Sentiment

Score: 3

Explanation: The sentiment is low due to the explicit 'going concern' warning from the auditor, persistent net losses, and negative working capital. While there is revenue growth and strategic plans, the fundamental financial health raises significant red flags for investors, indicating high risk.

Positives

• Net revenues increased by 12.4% from RMB304.9 million in 2023 to RMB342.6 million (US$46.9 million) in 2024.
• Internet hospital revenue grew by 25.4% from RMB71.0 million in 2023 to RMB89.0 million (US$12.2 million) in 2024, driven by online pharmacy sales.
• Pharmaceutical supply chain revenue increased by 8.4% from RMB233.8 million in 2023 to RMB253.5 million (US$34.7 million) in 2024, primarily from pharmacy wholesale.
• Gross profit increased from RMB38.7 million in 2023 to RMB47.7 million (US$6.5 million) in 2024, with gross profit margin improving from 12.7% to 13.9%.
• The company maintained high retention rates for mature doctors (99.9% in 2023, 99.4% in 2024) and a strong 90-day patient repurchase rate (63.7% in 2023, 66.2% in 2024).
• Average revenue per paying patient increased from RMB714 in 2023 to RMB766 in 2024.
• PomDoctor is ranked sixth in China's Internet hospital market by number of contracted doctors (over 212,800 as of December 31, 2024).
• The company has obtained online medical insurance payment qualification from Guangzhou Municipal Medical Security Bureau, with plans for broader expansion.
• The digital healthcare industry in China is projected to grow significantly, from RMB540.7 billion in 2022 to RMB1,525.9 billion in 2027 (CAGR of 23.1%).
• The company's auditor, Marcum Asia CPAs LLP, is headquartered in New York and is subject to regular PCAOB inspections, mitigating delisting risks under the HFCAA as PCAOB secured full access to inspect firms in mainland China and Hong Kong as of December 15, 2022.
• The company has completed the required CSRC filing procedures for this offering, with results published on January 17, 2025.

Negatives

• The company has incurred net losses of RMB36.9 million in 2023 and RMB37.4 million (US$5.1 million) in 2024.
• Negative cash flows from operating activities were RMB45.8 million in 2023 and RMB16.1 million (US$2.2 million) in 2024.
• The company had a significant accumulated deficit of RMB2,263.4 million (US$310.1 million) as of December 31, 2024.
• Working capital deficit increased from RMB112.6 million in 2023 to RMB141.6 million (US$19.4 million) in 2024.
• The auditor's report includes an explanatory paragraph expressing 'substantial doubt' about the company's ability to continue as a going concern.
• The gross profit margin of the Internet hospital segment decreased from 50.1% in 2023 to 42.7% in 2024, mainly due to increased online pharmacy sales of lower-margin products.
• Sales and marketing expenses increased by 29.0% from RMB43.7 million in 2023 to RMB56.4 million (US$7.7 million) in 2024.
• The company has a limited operating history in an emerging and dynamic Internet + healthcare industry, making historical results not indicative of future performance.
• The company has not been in full compliance with PRC labor laws and regulations regarding social insurance and housing provident fund contributions for some employees, with unpaid amounts of RMB2.6 million for both 2023 and 2024.
• The company has a limited number of key suppliers, with one supplier accounting for 39.1% of total purchases in 2024, posing supply chain concentration risk.
• The company has significant outstanding loans from related parties, totaling RMB370.5 million (US$50.8 million) as of December 31, 2024, with a substantial portion due in 2026.
• The company currently does not have cash management policies dictating how funds are transferred between the Company, its Hong Kong subsidiary, WFOE, VIE, and investors, relying on PRC laws and regulations.

Risks

• Substantial doubt about the company's ability to continue as a going concern due to net losses, negative operating cash flows, and working capital deficit.
• Reliance on Variable Interest Entity (VIE) structure in China, which may not be as effective as direct ownership and faces substantial uncertainties regarding interpretation and application of current and future PRC laws and regulations.
• Risk of severe penalties or forced relinquishment of interests in the VIE if the PRC government deems contractual arrangements non-compliant with foreign investment restrictions.
• Potential conflicts of interest with VIE shareholders who may breach or refuse to renew contractual arrangements.
• Uncertainties with respect to the enforcement of PRC laws and changes in laws and regulations in China, which could adversely affect business operations and the value of ADSs.
• Significant oversight and discretion by PRC governmental authorities over business operations, potentially limiting or hindering ability to offer securities or causing value decline.
• Reliance on dividends and other distributions from PRC subsidiaries to fund cash and financing requirements, which may be limited by PRC laws and regulations on profit distribution and capital controls.
• Risk of trading prohibition under the Holding Foreign Companies Accountable Act (HFCAA) if the PCAOB determines it cannot inspect or investigate the auditor for two consecutive years in the future.
• Exposure to medical liability claims in connection with online healthcare services, as the company does not carry insurance covering medical malpractice claims for doctors on its platform.
• Failure of doctors on the platform to provide adequate and proper medical services or comply with PRC practicing regulations, leading to penalties or reputational damage.
• Stringent scrutiny on the sale of prescription drugs in China, with evolving regulations (e.g., Measures for the Supervision and Administration of Online Pharmaceuticals Sales) that may expose the company to non-compliance risks.
• Inability to develop existing information infrastructure and technologies or recoup investments, and failure to innovate or adapt to changing user requirements or industry standards.
• Security breaches and attacks against systems and network, leading to unauthorized data release, reputational harm, and legal liability.
• Dependence on effective use of mobile operating systems, networks, and standards not controlled by the company, which could impact user growth and activity.
• Inability to conduct marketing activities cost-effectively and limitations in promoting healthcare-related services and products due to stringent PRC advertising laws.
• Failure to rectify and maintain an effective system of internal control over financial reporting, potentially leading to inaccurate financial reporting or fraud.
• Risks related to natural disasters, health epidemics (like COVID-19), and other outbreaks that could significantly disrupt operations.
• Potential for legal proceedings, litigation, or administrative disputes that could materially and adversely affect reputation, business, and financial condition.
• Risk of being classified as a PRC resident enterprise for tax purposes, which could result in unfavorable tax consequences for the company and non-PRC shareholders.
• Uncertainties with respect to indirect transfers of equity interests in PRC resident enterprises by non-PRC holding companies, potentially leading to PRC tax liabilities.
• Potential for governmental investigations or enforcement actions under Anti-Monopoly Guidelines for Internet Platforms and other anti-monopoly laws.
• Difficulties for overseas regulators to conduct investigations or collect evidence within China, limiting legal protection for U.S. investors.
• Substantial future sales or perceived potential sales of ADSs in the public market could cause the price to decline due to lock-up expirations and potential registrations.
• Dual-class voting structure limits the ability of Class A ordinary shareholders to influence corporate matters and could discourage change of control transactions.
• ADS holders may not be entitled to a jury trial with respect to claims arising under the deposit agreement, potentially resulting in less favorable outcomes.
• The company does not expect to pay dividends in the foreseeable future, requiring investors to rely on price appreciation for returns.
• Immediate and substantial dilution for new investors due to the initial public offering price being substantially higher than the net tangible book value per share.
• Increased costs as a public company, particularly after ceasing to qualify as an emerging growth company.

Future Outlook

PomDoctor plans to continue recruiting quality doctors and attracting more patient users, expand and strengthen its presence in key Chinese cities and provinces, enhance supply chain capabilities, and invest further in research and development. The company also aims to explore new patient acquisition channels through enhanced B2B collaborations, utilize accumulated big data to empower the industry, and expand its chronic disease management expertise to more medical areas. The company anticipates that the Chinese government's exploration of integrating the medical system with online medical services platforms will provide clearer access to the national health insurance system in other areas, allowing for diversified payment methods.

Management Comments

• "Our mission is to provide effective prevention and treatment solutions to alleviate patients sufferings from illnesses."
• "Our vision is to become the most trustworthy medical and healthcare services platform."
• "We believe that doctors are the most important resource in the medical services industry."
• "We strategically chose to focus on this field because chronic diseases last at least one year by definition, and they are hard to cure, prone to complications and require ongoing medical attention."
• "We do not expect to launch similar advertising and marketing campaigns [as with Focus Media] in the future."
• "We will assess the marketing and media effectiveness continuously based on web traffic, conversion rates, return on investment and other performance metrics as applicable, and we strive to optimize the efficiency of our advertising and marketing expenditures based on such data."
• "Our liquidity is based on our ability to generate cash from operating activities, debt financing and capital contributions from our shareholders to fund its general operations and capital expansion needs."
• "Our ability to continue as a going concern is dependent on managements ability to successfully execute its business plan, which includes generating revenue while controlling operating cost and expenses to generate positive operating cash flows and obtaining funds from outside sources of financing to generate positive financing cash flows."

Industry Context

PomDoctor operates in China's rapidly expanding digital healthcare industry, particularly focusing on chronic disease management (CDM). The industry is driven by increasing health awareness, favorable government policies promoting 'Internet+ Medical Health', and the transition from offline to online healthcare, accelerated by events like the COVID-19 pandemic. The market size of China's digital healthcare industry is projected to grow from RMB540.7 billion in 2022 to RMB1,525.9 billion in 2027, representing a CAGR of approximately 23.1%. The Internet CDM market specifically is expected to reach RMB778.6 billion by 2027. The industry faces challenges such as unequal distribution of medical resources and inefficiencies in traditional chronic disease management, which online platforms aim to address. Key trends include increasing doctor participation on online platforms, digitalization of consumer healthcare, and the growing importance of digital health infrastructure services.

Comparison to Industry Standards

• PomDoctor ranked sixth among participants in the China Internet Hospital Market in terms of the number of contracted doctors in 2022, with 212,000 contracted doctors.
• The company's average inventory turnover days are not explicitly stated for comparison, but the document notes that the average inventory turnover days of the top 5 offline pharmacies in China in 2022 were 87.8 days, compared with 26.3 days in the United States, indicating a general industry inefficiency in China that digital solutions aim to address.
• The company's retention rate for mature doctors (99.9% in 2023 and 99.4% in 2024) is described as 'top-level' among the industry, suggesting strong performance in this metric compared to competitors like Medlinker, Hao Daifu, and Ping An Good Doctor.
• The company's standing inventories of prescription drugs (6,000 to 7,000 SKUs) are significantly higher than a traditional public hospital (1,000 to 3,000 SKUs), indicating a broader product offering.
• The document mentions Teladoc Health, Inc. as an industry peer in exploring B2B patient acquisition models, implying a strategic alignment with global digital health trends.

Management Changes

Corporate Governance

Legal Proceedings

• The company is currently not a party to any material legal or administrative proceedings.
• The company may from time to time be subject to various legal or administrative claims and proceedings arising in the ordinary course of business, including medical disputes, fraud, misconduct, and data protection issues.

Related Party Transactions

• The company has significant outstanding loans from Mr. Zhenyang Shi, the CEO, totaling RMB135.7 million (US$18.6 million) as of December 31, 2024, with an annual interest rate of 4.90% and due December 31, 2026.
• An advertising liability of RMB221.0 million was transferred from Focus Media to Aixiangbao (a wholly-owned entity by Mr. Zhenyang Shi) on August 10, 2021, with the company agreeing to repay this debt to Aixiangbao in a non-cash method after five years (due August 10, 2026), bearing no interest.
• Loans from Ms. Li Xu, CEO's spouse, totaled RMB1.5 million (US$0.2 million) as of December 31, 2024, with varying interest rates and due dates.
• Loans from Aihua Peng, a close relative of a shareholder's management, totaled RMB4.0 million (US$0.6 million) as of December 31, 2024, with an annual interest rate of 20.00% and due on demand.
• Loans from other management personnel (Guoji Luo, Yongan Zhong, Dexiang Wei) were outstanding as of December 31, 2024, mostly interest-free and due on demand.
• The company had accounts receivable from Guangzhou Zhiyao Cloud Technology Co., Ltd. (a company controlled by management) of RMB424,259 (US$58,123) as of December 31, 2024, and drug sales to this entity of RMB1.2 million (US$0.2 million) in 2024.
• The company purchased drugs from Guangzhou Aopolikang Biotechnology Co., Ltd. (a company controlled by management) for RMB25,499 (US$3,493) in 2024.
• Several bank loans are guaranteed by Mr. Zhenyang Shi, Ms. Li Xu, and other related parties, and some are mortgaged by Mr. Zhenyang Shi's real property.

Stakeholder Impact

• **Shareholders**: Potential for significant dilution from future equity issuance. Limited influence on corporate matters due to dual-class voting structure. Risk of losing entire investment if the company cannot continue as a going concern. Potential for adverse U.S. federal income tax consequences if classified as a PFIC.
• **Employees**: Risk of job insecurity if the company's financial condition deteriorates. Non-compliance with PRC labor laws regarding social insurance and housing provident funds could impact employee benefits and lead to legal issues for the company. Share-based awards are intended to incentivize and retain key personnel.
• **Customers (Patients)**: Continued access to online medical services and pharmaceutical products. Potential for improved experience through technology enhancements and expanded service offerings. Risk of service disruption or quality issues if the company faces operational challenges or security breaches.
• **Suppliers**: Concentration risk with a few key suppliers. The company's ability to secure favorable terms depends on its scale and market position. Financial instability could impact timely payments to suppliers.
• **Creditors**: High risk due to the company's significant accumulated deficit, working capital deficit, and 'going concern' opinion. Reliance on related party loans and guarantees from management indicates potential difficulty in securing traditional financing.

Next Steps

• Complete the Initial Public Offering (IPO) on the Nasdaq Global Market.
• Implement measures to address material weaknesses in internal control over financial reporting, including hiring additional accounting and financial reporting personnel, strengthening financial reporting functions, and enhancing system logical access security.
• Continue to recruit quality doctors onto the platform and attract more patient users through online and onsite promotion.
• Expand and strengthen presence in key cities and provinces across China, leveraging offline medical institutions for Internet hospital qualifications and online medical insurance payment.
• Enhance supply chain capabilities by expanding product categories and supplier channels, and optimizing drug storage, distribution, and management.
• Continue to invest in research and development to update and optimize the Pom Doctor APP and WeChat official account, and enhance AI and big data analysis capabilities.
• Explore new patient acquisition channels via enhanced B2B collaborations, potentially with insurance companies.
• Utilize accumulated big data to empower the pharmaceutical industry, commercial insurance companies, and governmental authorities.
• Expand experience and reputation in chronic diseases to more medical areas, replicating the successful hepatopathy business model.

Key Dates

Recommendation

Keywords

Online Medical Services, Chronic Disease Management, Internet Hospital, Pharmaceutical Supply Chain, China Healthcare, SEC Filing, IPO, F-1/A, VIE Structure, Digital Health, Telemedicine, Prescription Drugs, Nasdaq, Going Concern, PRC Regulation, Healthcare Technology, Patient Management, Doctor Platform, Healthcare E-commerce